Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
:MRUS
MRUS Analyst Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRUS Stock 12 Month Forecast
Average Price Target
$91.91
▲(36.61% Upside)
| Highest Price Target$110.00 | Average Price Target$91.91 | Lowest Price Target$67.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Alliance Global Partners
$90
Buy
33.77%
Upside
Initiated
08/25/25
Canaccord Genuity
$67
Buy
-0.42%
Downside
Reiterated
08/14/25
TR | OpenAI - 4o
$67→$71
Hold
5.53%
Upside
Reiterated
08/14/25
Needham
$97→$96
Buy
42.69%
Upside
Reiterated
08/06/25
Leerink Partners
$95
Buy
41.20%
Upside
Reiterated
08/06/25
Wells Fargo
$89→$95
Buy
41.20%
Upside
Reiterated
08/06/25
H.C. Wainwright
$85
Buy
26.34%
Upside
Reiterated
08/06/25
William Blair
―
Buy
―
Reiterated
08/06/25
LifeSci Capital
$110
Buy
63.50%
Upside
Reiterated
08/05/25
s: Earlier this aernoon, MRUS provided 2Q 2025 earnings that highlighted recent milestones and largely re-iterated key near-term guidance, including 2H 2025 data for petosemtamab in CRC (see Petosemtamab CRC on EGFR Oncofetal CRC Cells; LGR5 and CRC Metastasis). We caught up with mgmt, who remained steadfast and consistent in their messaging heading into petosemtamab's much-ancipated 2H 2025 CRC readout. Consistent with our prior conversaons, mgmt noted their belief that investors will compare petosemtamab to amivantamab's CRC data and reiterated their view that JNJ was aggressive in pursuing registraonal development with their data on-hand.
Bank of America Securities
$92
Buy
36.74%
Upside
Reiterated
06/10/25
Guggenheim
$111→$109
Buy
62.01%
Upside
Reiterated
06/02/25
Truist Financial
―
Buy
―
Reiterated
06/02/25
BMO Capital
$96→$110
Buy
63.50%
Upside
Reiterated
05/23/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Alliance Global Partners
$90
Buy
33.77%
Upside
Initiated
08/25/25
Canaccord Genuity
$67
Buy
-0.42%
Downside
Reiterated
08/14/25
TR | OpenAI - 4o
$67→$71
Hold
5.53%
Upside
Reiterated
08/14/25
Needham
$97→$96
Buy
42.69%
Upside
Reiterated
08/06/25
Leerink Partners
$95
Buy
41.20%
Upside
Reiterated
08/06/25
Wells Fargo
$89→$95
Buy
41.20%
Upside
Reiterated
08/06/25
H.C. Wainwright
$85
Buy
26.34%
Upside
Reiterated
08/06/25
William Blair
―
Buy
―
Reiterated
08/06/25
LifeSci Capital
$110
Buy
63.50%
Upside
Reiterated
08/05/25
s: Earlier this aernoon, MRUS provided 2Q 2025 earnings that highlighted recent milestones and largely re-iterated key near-term guidance, including 2H 2025 data for petosemtamab in CRC (see Petosemtamab CRC on EGFR Oncofetal CRC Cells; LGR5 and CRC Metastasis). We caught up with mgmt, who remained steadfast and consistent in their messaging heading into petosemtamab's much-ancipated 2H 2025 CRC readout. Consistent with our prior conversaons, mgmt noted their belief that investors will compare petosemtamab to amivantamab's CRC data and reiterated their view that JNJ was aggressive in pursuing registraonal development with their data on-hand.
Bank of America Securities
$92
Buy
36.74%
Upside
Reiterated
06/10/25
Guggenheim
$111→$109
Buy
62.01%
Upside
Reiterated
06/02/25
Truist Financial
―
Buy
―
Reiterated
06/02/25
BMO Capital
$96→$110
Buy
63.50%
Upside
Reiterated
05/23/25
Best Analysts Covering Merus
1 Month
xxx
Success Rate
7/13 ratings generated profit
Average Return
+4.25%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +4.25% per trade.
3 Months
xxx
Success Rate
11/13 ratings generated profit
Average Return
+22.59%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +22.59% per trade.
1 Year
Success Rate
11/13 ratings generated profit
Average Return
+29.95%
reiterated a buy rating 3 months ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +29.95% per trade.
2 Years
xxx
Success Rate
28/28 ratings generated profit
Average Return
+98.99%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +98.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRUS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
22
28
28
26
8
Buy
7
14
17
15
14
Hold
6
12
10
7
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
54
55
48
24
Each month's total comprises the sum of three months' worth of ratings.
MRUS Financial Forecast
MRUS Stock Forecast FAQ
What is MRUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Merus NV’s 12-month average price target is 91.91.
What is MRUS’s upside potential, based on the analysts’ average price target?
Merus NV has 36.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRUS a Buy, Sell or Hold?
Merus NV has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
What is Merus NV’s price target?
The average price target for Merus NV is 91.91. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $67.00. The average price target represents 36.61% Increase from the current price of $67.28.
The highest analyst price target is $110.00 ,the lowest forecast is $67.00. The average price target represents 36.61% Increase from the current price of $67.28.
What do analysts say about Merus NV?
Merus NV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of MRUS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.